Want to see CH:EVE full AI Analyst Report?
EVE Stock Chart & Stats
CHF0.82
CHF0.10(7.88%)
At close: 4:00 PM EST
CHF0.82
CHF0.10(7.88%)
Day’s Range― - ―
52-Week RangeCHF0.75 - CHF2.40
Previous CloseN/A
Volume16.51K
Average Volume (3M)6.26K
Market Cap
CHF17.31M
Enterprise ValueCHF6.22M
Total Cash (Recent Filing)CHF6.31M
Total Debt (Recent Filing)CHF0.00
Price to Earnings (P/E)―
Beta0.38
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding7,230,626
10 Day Avg. Volume6,146
30 Day Avg. Volume6,263
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.98
Price to Sales (P/S)0.00
P/FCF Ratio-2.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.5
Revenue Forecast (FY)CHF60.90M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA zero-debt capital structure materially lowers bankruptcy and interest-rate risk, preserving strategic optionality. Over 2–6 months this supports funding flexibility for R&D, licensing or pivot initiatives without immediate refinancing pressure, improving resilience.
Improved 2024 ProfitabilityRecording positive EBIT and net income in 2024 indicates management can cut costs or realign operations to profitability. If sustained alongside a revived revenue base, this structural improvement increases the likelihood of self-funded operations and stronger partner outcomes.
Lean Operating FootprintA small workforce implies a lower fixed-cost base, which durablely reduces cash burn while the business repositions. Over months this makes runway extension via cost control more feasible and enables nimble redeployment of resources toward higher-return projects or partnerships.
Bears Say
Revenue Fell To Zero In 2024A complete loss of reported revenue is a structural business-model failure: without sustainable sales or recurring income, profitability and cash metrics are fragile. Over 2–6 months, absent new commercial traction this undermines credibility with partners and access to non-dilutive funding.
Negative Free Cash Flow TrendPersistent negative operating and free cash flow indicates structural cash burn despite accounting profits in 2024. Over the medium term this forces reliance on external financing or asset sales, constraining strategic investments and increasing dilution or refinancing risk.
Compressed Equity And Asset BaseShrinking assets and equity materially reduce balance-sheet firepower for R&D, licensing, or commercialization. Over several months this lowers collateral for lenders, limits ability to absorb shocks, and narrows strategic options like partnerships or acquisitions that require capital backing.
Evolva Holding News
EVE FAQ
What was Evolva Holding’s price range in the past 12 months?
Evolva Holding lowest stock price was CHF0.75 and its highest was CHF2.40 in the past 12 months.
What is Evolva Holding’s market cap?
Evolva Holding’s market cap is CHF17.31M.
When is Evolva Holding’s upcoming earnings report date?
Evolva Holding’s upcoming earnings report date is Aug 26, 2026 which is in 57 days.
How were Evolva Holding’s earnings last quarter?
Evolva Holding released its earnings results on Apr 29, 2026. The company reported -CHF0.04 earnings per share for the quarter, missing the consensus estimate of N/A by -CHF0.04.
Is Evolva Holding overvalued?
According to Wall Street analysts Evolva Holding’s price is currently Overvalued.
Does Evolva Holding pay dividends?
Evolva Holding does not currently pay dividends.
What is Evolva Holding’s EPS estimate?
Evolva Holding’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Evolva Holding have?
Evolva Holding has 7,230,626 shares outstanding.
What happened to Evolva Holding’s price movement after its last earnings report?
Evolva Holding reported an EPS of -CHF0.04 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.04%.
Which hedge fund is a major shareholder of Evolva Holding?
Currently, no hedge funds are holding shares in CH:EVE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Evolva Holding
EvoNext Holdings SA is dedicated to the exploration, creation, and distribution of pioneering ingredients across the nutritional, health, and wellness domains. Founded in 2004, the company's inception is attributed to Alexandra Santana Sørensen, Søren V. S. Nielsen, and Neil Goldsmith. Its corporate headquarters are located in Reinach, Switzerland.
Technical Analysis
Molecular Partners AG
―
Newron Pharmaceuticals SpA
―
Santhera Pharmaceuticals Holding
―
―
Xlife Sciences Ltd.
―
Options Prices
Currently, No data available
---



